IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. - Wikidata - awgldk - TriplyDB

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

http://www.wikidata.org/entity/Q51827137

about

Bone Marrow Immunity and Myelodysplasia Signal transduction inhibitors in treatment of myelodysplastic syndromes Infections in myelodysplastic syndromes Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes The complex pathophysiology of acquired aplastic anaemia Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.Current therapy of myelodysplastic syndromes Th17 immune responses contribute to the pathophysiology of aplastic anemia.Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Immune dysregulation in myelodysplastic syndrome.Bone marrow and the control of immunity.T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone.Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome: A Retrospective Cohort Study.Th17 and Treg cells in bone related diseases.Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells Specific plasma autoantibody reactivity in myelodysplastic syndromes.Immunological derangement in hypocellular myelodysplastic syndromes.NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.Immune alterations in untreated and treated myelodysplastic syndrome.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum.A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.The inflammatory microenvironment in MDS.Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.

P2860

Q26739239-9132943C-F869-4ABC-ACB4-B3BA22614C7D Q26829903-2AE3FF35-54B3-48AF-8964-0B2BDA48ED7A Q26859275-7C4EDF9C-3F40-4F0C-B542-A71E92F126DC Q26864200-5200DEA9-E165-492E-BAE9-99F7B63626B1 Q27015288-77ACF38A-A07F-40C4-BDE8-9C6B4FE4CF51 Q28082135-1664C029-9F62-4683-9BE9-2A5AFD0BC78A Q28662217-AC5EEED6-D78B-4644-978A-7755106A46E1 Q33442467-C09AA5F0-91C7-4B75-A33F-20F4B4CC26D5 Q33702157-E13C9031-15B0-47A5-A899-FF899162B05D Q34013796-E440EB68-8BC3-46F1-86B9-7F6356DD48F1 Q34360341-C83A1E5E-A6CE-44BF-A9DA-137638A52055 Q34510880-F57FC2C9-F773-4D86-BE07-0091B0DF3E0D Q34613086-0F2D6894-3B34-4D6A-B556-FCA2E0423105 Q35040785-5B1B1F01-F2A1-497F-AC7A-38677F526239 Q35136851-DC406515-5B4E-4532-A74E-F75825B563F6 Q35567932-02B24A51-15CA-47E7-93E4-BAD91AB9C6C3 Q35653129-E6A795AA-5988-4A97-98FF-3E54C520F256 Q36717261-50323290-8826-43F7-8FB7-27E74FD93246 Q36909178-98FD1F19-3569-4131-80AF-B8C97026A5D9 Q36963592-C2C7866F-FE2F-4B16-ABD4-59E50F4D383A Q37060639-A92BE6E2-47D4-4794-A698-FE7F706761B4 Q37134517-7CCA5F4A-3C21-44CD-A9C6-360F988E96AF Q37205862-8A92CABE-A4BD-4B11-A471-CA7C59FC167F Q37239790-33072A4C-722E-4BB8-83E6-46F1D1FFD332 Q37303329-58D24016-58DF-4F3C-A871-72D6B87B47DD Q37334237-42A453F9-691B-4F4D-98BE-8D277EA81A60 Q37724605-4B6FC413-28ED-45BF-9FAC-F87E0C2C9298 Q37790694-2A59F065-9148-428E-ABF5-E1E52D2378F1 Q37854701-57D4C169-476B-4CDA-9BDB-FAED9FA17950 Q37864686-5875FC8A-740B-42EB-BB50-E696B51C7F9A Q37980495-4053C3F4-C0DC-4853-8251-8FF13EDE8977 Q38037118-FB80FBEA-9D5C-4D49-A33F-1C74F8621364 Q38083604-F3B5BF53-4206-4A4C-9196-0B88861CEB51 Q38110935-7C7BF304-4D43-4061-8C01-BC895B0093A2 Q38194601-1D98AE97-8C50-4339-9ACE-75841C2E2CA5 Q38259434-17F41D89-3318-48B5-9282-6A382A9AA6AF Q38283075-7D7520BD-9965-40C4-99D7-8905FFC0A85A Q38348119-965D76D4-A9A1-4CF6-BA33-89502A1EFE45 Q38540015-859FC1ED-60AC-4223-B1B3-12E93C963E62 Q38826127-46ED500E-61F3-4106-8E9C-C121ECB645FD

P2860

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.

http://www.wikidata.org/entity/Q51827137

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@en

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@nl

type

label

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@en

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@nl

prefLabel

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@en

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@nl

P1433

Q51827137-91A2CB01-2EB8-43C3-88EB-0EFE0CCD05D9

P1476

Q51827137-BF21AD43-AB14-44F2-9891-77B9BB484E41

P2093

Q51827137-1EBC663A-5047-4E72-8F71-88BC4F42BBB4

Q51827137-65A36832-B61F-43DF-B3E9-A89E33D22B89

Q51827137-7F4420CB-1B76-427F-BD52-FB79F9B82A4B

Q51827137-84E2258C-EF99-4DA6-8872-C34B612A669A

Q51827137-9AE9322A-BB13-4044-B942-DDD4F4090495

Q51827137-9B0C52C5-9650-4FB6-88FC-5F1CD09B634B

Q51827137-B5899C1F-0289-4994-B8AD-248016F6FD1D

Q51827137-C906CECA-401D-40E4-9A51-59B2ACD8331E

P2860

Q51827137-2E932638-5BFD-4A5E-9AF5-D4C49A0ECB29

Q51827137-71DEB64A-B968-47B8-BBA4-1FB6404D9746

P304

Q51827137-CE1A6A4D-9BF3-4530-80AC-74CC95C1A1B1

P31

Q51827137-20844E30-FA05-4E02-AC67-F7EAF27EF99B

P356

Q51827137-419EDB8F-079C-4E5E-A225-93D084300744

P407

Q51827137-46A6BDE9-68A5-4799-A8A7-C01E6F6A8F53

P433

Q51827137-434AE12C-8BEE-4A89-B7D8-230631FCFA00

P478

Q51827137-9E11CA31-BF46-42AA-8267-348C5F39B284

P50

Q51827137-43892F55-031B-411B-8F80-C61020EC9E63

Q51827137-7B9D3386-B514-470A-81D1-784CEEC99076

Q51827137-8682D8C0-C66C-49B1-8EAC-1EF1715DC112

Q51827137-A687C60F-6EC8-44E8-AC6D-61BAC92BFB2A

P577

Q51827137-E0E08D93-31F3-4050-8152-E24869E40F84

P5875

Q51827137-956B619C-D6B0-4CDA-ACC6-5F16F2D7CC13

P698

Q51827137-BB5D89B1-7DE7-4015-9A2E-E099B131BBBC

P356

J.1365-2141.2009.07593.X

P1433

British Journal of Haematology

P1476

IL-17-producing CD4(+) T cells ...... risk myelodysplastic syndrome.

@en

P2093

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Giovanna Lombardi

http://www.w3.org/2001/XMLSchema#string

Janet Hayden

http://www.w3.org/2001/XMLSchema#string

Katie Matthews

http://www.w3.org/2001/XMLSchema#string

Linda Barber

http://www.w3.org/2001/XMLSchema#string

Rajani Chelliah

http://www.w3.org/2001/XMLSchema#string

Wendy Ingram

http://www.w3.org/2001/XMLSchema#string

Ziyi Lim

http://www.w3.org/2001/XMLSchema#string

P2860

The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.

Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.

P304

64-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07593.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

145

http://www.w3.org/2001/XMLSchema#string

P50

Farzin Farzaneh

Shahram Kordasti

P577

2009-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24001651

http://www.w3.org/2001/XMLSchema#string

P698

19210506

http://www.w3.org/2001/XMLSchema#string